Cisatracurium besilate: A new nondepolarizing neuromuscular relaxant

[1] Bryson H.M., Faulds D., Cisatracurium besilate: A review of its pharmacology and clinical potential in anaesthetic practice, Drugs, 53, 5, pp. 849-866, (1997)

[2] British National Formulary No. 31, pp. 530-531, (1996)

[3] Schmautz E., Deriaz H., Vrillon M., Et al., Evaluation of 51W89 for endotracheal intubation in surgical patients during N₂O/O₂/propofol anesthesia [abstract no. A1081], Anesthesiology, 81, SUPPL. 3A, (1994)

[4] Bluestein L.S., Stinson Jr. L.W., Lennon R.L., Et al., Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation, Can J Anaesth, 43, pp. 925-931, (1996)

[5] Littlejohn I.H., Abhay K., El Sayed A., Et al., Intubating conditions following IR CIS, I'R CIS atracurium (51W89): A comparison with atracurium, Anaesthesia, 50, pp. 499-502, (1995)

[6] Pavlin E.G., Duvaldestin P., Belmont M.R., Et al., The use of cisatracurium for tracheal intubation, Curr Opin Anaesth, 9, 1 SUPPL., pp. 523-526, (1996)

[7] Stout R.G., Belmont M.R., Pavlin E.G., Et al., Evaluation of intubation at 90 and 120 seconds following 51W89 administration [abstract no. A1078], Anesthesiology, 81, SUPPL. 3A, (1994)

[8] Prielipp R.C., Coursin D.B., Scuderi P.E., Et al., Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients, Anesth Analg, 81, pp. 3-12, (1995)

[9] Chapple D.J., Miller A.A., Ward J.B., Et al., Cardiovascular and neurological effects of laudanosine: Studies in mice and rats, and in conscious and anaesthetized dogs, Br J Anaesth, 59, pp. 218-225, (1987)

[10] Lepage J.Y., Malinovsky J.M., Malinge M., Et al., Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N₂O-O₂-opioid anesthesia, Anesth Analg, 83, pp. 823-829, (1996)

[1] Bryson H.M., Faulds D., Cisatracurium besilate: A review of its pharmacology and clinical potential in anaesthetic practice, Drugs, 53, 5, pp. 849-866, (1997)

[2] British National Formulary No. 31, pp. 530-531, (1996)

[3] Schmautz E., Deriaz H., Vrillon M., Et al., Evaluation of 51W89 for endotracheal intubation in surgical patients during N₂O/O₂/propofol anesthesia [abstract no. A1081], Anesthesiology, 81, SUPPL. 3A, (1994)

[4] Bluestein L.S., Stinson Jr. L.W., Lennon R.L., Et al., Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation, Can J Anaesth, 43, pp. 925-931, (1996)

[5] Littlejohn I.H., Abhay K., El Sayed A., Et al., Intubating conditions following IR CIS, I'R CIS atracurium (51W89): A comparison with atracurium, Anaesthesia, 50, pp. 499-502, (1995)

[6] Pavlin E.G., Duvaldestin P., Belmont M.R., Et al., The use of cisatracurium for tracheal intubation, Curr Opin Anaesth, 9, 1 SUPPL., pp. 523-526, (1996)

[7] Stout R.G., Belmont M.R., Pavlin E.G., Et al., Evaluation of intubation at 90 and 120 seconds following 51W89 administration [abstract no. A1078], Anesthesiology, 81, SUPPL. 3A, (1994)

[8] Prielipp R.C., Coursin D.B., Scuderi P.E., Et al., Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients, Anesth Analg, 81, pp. 3-12, (1995)

[9] Chapple D.J., Miller A.A., Ward J.B., Et al., Cardiovascular and neurological effects of laudanosine: Studies in mice and rats, and in conscious and anaesthetized dogs, Br J Anaesth, 59, pp. 218-225, (1987)

[10] Lepage J.Y., Malinovsky J.M., Malinge M., Et al., Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N₂O-O₂-opioid anesthesia, Anesth Analg, 83, pp. 823-829, (1996)